As more and more immune checkpoints are identified, and their mechanisms of action elucidated, new options for single and combined therapy regimens can be derived. Combining different checkpoint blockade agents may produce potent effects, due in part to targeting more than one immune pathways.
Figure 1. Target landscapes of combination trials in 2019 and 2017.
Based on the different inhibitory pathways of CTLA-4 and PD-1 on T cells, the combination therapy that targets both pathways may therefore augment the activity of each other by overcoming the limitations of each monotherapy. While CTLA-4 and PD-1 are the most-extensively researched targets, results from pre-clinical studies and clinical trials indicate that novel agents, specific for checkpoints such as A2AR, LAG-3, IDO and others, may further contribute to the improvement of patient outcomes, most likely in combinations with anti-CTLA-4 or anti-PD-1 blockade.
Additionally, BioCytoceuticals offers our unparalleled human knock-in mice with a broad range of immune checkpoints, and the number is still increasing. We are also happy to construct custom transgenic mice/rats upon request. We have successfully launched an array of well-characterized humanized animal models, which can provide you with the humanized combining immune checkpoint knock-in mice.
Figure 2. Co-targeting of RANKL with PD1/PD-L1 alone or in combination with CTLA-4 suppresses subcutaneous tumor growth.
BioCytoceuticals leads the industry in cellular therapy with commitment to providing the most appropriate solutions to address the needs of our clients. Our expert team of scientists applies comprehensive methods and the most detail-oriented scrutiny to ensure only top-tier outcome is submitted. We provide comprehensive services and products for customer, including humanized mouse models and their related services.
If you have any special enquiries regarding our Immune Checkpoint Inhibitor service, please do not hesitate to contact us. Our highly professional technical supporting staffs will make sure your requests are faithfully received. We are looking forward to earning your business.
Inquiry
